Triglyceride-Glucose Index and New-Onset Atrial Fibrillation in ST-Segment Elevation Myocardial Infarction Patients After Percutaneous Coronary Intervention.
ST-segment elevation myocardial infarction
TyG index
insulin resistance
new-onset atrial fibrillation
percutaneous coronary intervention
prognosis
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
12
2021
accepted:
04
02
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
30
3
2022
Statut:
epublish
Résumé
New-onset atrial fibrillation (NOAF) is associated with worse prognostic outcomes in cases diagnosed with ST-segment elevation myocardial infarction (STEMI) patients after percutaneous coronary intervention (PCI). The triglyceride-glucose (TyG) index, as a credible and convenient marker of insulin resistance, has been shown to be predictive of outcomes for STEMI patients following revascularization. The association between TyG index and NOAF among STEMI patients following PCI, however, has not been established to date. To assess the utility of the TyG index as a predictor of NOAF incidence in STEMI patients following PCI, and to assess the relationship between NOAF and long-term all-cause mortality. This retrospective cohort research enrolled 549 STEMI patients that had undergone PCI, with these patients being clustered into the NOAF group and sinus rhythm (SR) group. The predictive relevance of TyG index was evaluated through logistic regression analyses and the receiver operating characteristic (ROC) curve. Kaplan-Meier curve was employed to explore differences in the long-term all-cause mortality between the NOAF and SR group. NOAF occurred in 7.7% of the enrolled STEMI patients after PCI. After multivariate logistic regression analysis, the TyG index was found to be an independent predictor of NOAF [odds ratio (OR): 8.884, 95% confidence interval (CI): 1.570-50.265, The TyG index exhibits values as an independent predictor of NOAF during hospitalization, which indicated a poorer prognosis after a relatively long-term follow-up.
Sections du résumé
Background
UNASSIGNED
New-onset atrial fibrillation (NOAF) is associated with worse prognostic outcomes in cases diagnosed with ST-segment elevation myocardial infarction (STEMI) patients after percutaneous coronary intervention (PCI). The triglyceride-glucose (TyG) index, as a credible and convenient marker of insulin resistance, has been shown to be predictive of outcomes for STEMI patients following revascularization. The association between TyG index and NOAF among STEMI patients following PCI, however, has not been established to date.
Objective
UNASSIGNED
To assess the utility of the TyG index as a predictor of NOAF incidence in STEMI patients following PCI, and to assess the relationship between NOAF and long-term all-cause mortality.
Methods
UNASSIGNED
This retrospective cohort research enrolled 549 STEMI patients that had undergone PCI, with these patients being clustered into the NOAF group and sinus rhythm (SR) group. The predictive relevance of TyG index was evaluated through logistic regression analyses and the receiver operating characteristic (ROC) curve. Kaplan-Meier curve was employed to explore differences in the long-term all-cause mortality between the NOAF and SR group.
Results
UNASSIGNED
NOAF occurred in 7.7% of the enrolled STEMI patients after PCI. After multivariate logistic regression analysis, the TyG index was found to be an independent predictor of NOAF [odds ratio (OR): 8.884, 95% confidence interval (CI): 1.570-50.265,
Conclusions
UNASSIGNED
The TyG index exhibits values as an independent predictor of NOAF during hospitalization, which indicated a poorer prognosis after a relatively long-term follow-up.
Identifiants
pubmed: 35345486
doi: 10.3389/fcvm.2022.838761
pmc: PMC8957253
doi:
Types de publication
Journal Article
Langues
eng
Pagination
838761Informations de copyright
Copyright © 2022 Ling, Fu, Fan, Liu, Jiang and Tang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Front Cardiovasc Med. 2021 Sep 22;8:677695
pubmed: 34631808
Metab Syndr Relat Disord. 2008 Dec;6(4):299-304
pubmed: 19067533
Nat Rev Cardiol. 2010 Oct;7(10):577-84
pubmed: 20697411
Cardiovasc Diabetol. 2019 Nov 13;18(1):150
pubmed: 31722708
Int J Clin Pract. 2018 Apr;72(4):e13087
pubmed: 29665154
Ann Intern Med. 2006 Aug 15;145(4):247-54
pubmed: 16908915
Ann Med. 2018 Nov;50(7):576-586
pubmed: 30207490
Front Cardiovasc Med. 2021 Jul 23;8:692511
pubmed: 34368252
J Cardiol. 2018 Feb;71(2):125-128
pubmed: 28969967
Eur J Prev Cardiol. 2020 Dec;27(18):1934-1941
pubmed: 32122201
Eur Heart J. 2009 May;30(9):1038-45
pubmed: 19109347
Cardiovasc Diabetol. 2017 Sep 29;16(1):120
pubmed: 28962617
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt A):987-996
pubmed: 29291943
Am J Cardiol. 2011 Jul 1;108(1):56-62
pubmed: 21529739
Cardiovasc Diabetol. 2014 Oct 20;13:146
pubmed: 25326814
Circ Res. 2018 Mar 2;122(5):752-773
pubmed: 29496798
Int J Cardiol. 2017 Aug 1;240:228-233
pubmed: 28390742
Circ Res. 2018 Feb 16;122(4):624-638
pubmed: 29449364
Circulation. 2011 Apr 19;123(15):1587-93
pubmed: 21464054
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Am Heart J. 2021 Aug;238:89-99
pubmed: 33957102
Front Cardiovasc Med. 2020 Nov 27;7:610322
pubmed: 33330672
Coron Artery Dis. 2012 Jan;23(1):1-8
pubmed: 22107800
Circulation. 2000 Mar 7;101(9):969-74
pubmed: 10704162
Cardiovasc Diabetol. 2018 Aug 31;17(1):122
pubmed: 30170598
Diabetes Res Clin Pract. 2015 Sep;109(3):476-84
pubmed: 26220013
Am J Cardiol. 2014 Jan 15;113(2):236-42
pubmed: 24176066
Heart. 2016 Jun 15;102(12):926-33
pubmed: 26928408
Crit Rev Clin Lab Sci. 2015;52(4):180-90
pubmed: 26042993
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1754-9
pubmed: 22815340
Int Heart J. 2009 Sep;50(5):627-41
pubmed: 19809211
Chest. 2007 Jul;132(1):44-9
pubmed: 17400657
Cardiovasc Diabetol. 2019 Jul 25;18(1):95
pubmed: 31345238
Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26
pubmed: 17957034
EuroIntervention. 2005 Aug;1(2):219-27
pubmed: 19758907
Eur J Clin Invest. 2016 Feb;46(2):189-97
pubmed: 26683265
J Clin Endocrinol Metab. 2010 Jul;95(7):3347-51
pubmed: 20484475
Cardiovasc Diabetol. 2019 Sep 26;18(1):125
pubmed: 31558158